Answer from: Medical Oncologist at Community Practice
While there are no FDA-approved biomarkers predictive of iAEs, there is a growing body of preclinic and retrospective research trying to address this important question. Eosinophilia may be a potentially useful biomarker and this is supported by several retrospective studies 1,2. It is intrigui...
Comments
Medical Oncologist at Stephen B. Strum, MD PC I started off in pathology before going into HemOn...
Answer from: Medical Oncologist at Community Practice
Currently, there are no validated biomarkers for predicting which patients treated with ICPi’s will develop irAEs, although this is an active area of investigation with emerging signals that appear to correlate with certain irAEs.
I started off in pathology before going into HemOn...